This payload class offers a significant therapeutic advantage by targeting metabolic vulnerabilities in cancer cells and broadening the effectiveness of ADCs beyond the classical paradigm of highly cytotoxic chemotherapy, making NAMPT inhibitors an attractive payload option for next-generation ADC development in both solid and hematological malignancies [134,135,136]. This evidence concerns the gene NAMPT and cancer.